Under 10% of individuals that would benefit from obesity jabs such as Wegovy can access them, states the WHO as it releases its initial advice on the therapies.
With in excess of 1,000,000,000 individuals worldwide now living with obesity, it is advocating for broader and more equitable availability to GLP-1 medication.
Per forecasts, in excess of 2,000,000,000 could be living with obesity by 2030 unless action is taken.
"Our new guidelines recognises that obesity is a long-term condition that can be managed with comprehensive and lifelong care," stated its chief Tedros Adhanom Ghebreyesus.
Significant expense, insufficient output, and logistical bottlenecks are significant obstacles to universal availability to the jabs that can aid individuals in losing substantial body mass, notes the agency.
GLP-1 Therapy Shortage
Even in the present best projected scenario, the manufacturing of these medications might only reach around 100 million people – fewer than 10% of the global need, per the health organization.
The recommendation urges nations and manufacturers to widen access, through strategies like licensing agreements.
The intellectual property rights on a key compound – the main component of a leading brand – is set to lapse in multiple nations in 2026.
How Obesity Injections Work
GLP-1 drugs replicate a body's own hormone to reduce digestion speed, curb appetite and boost the sense of being full so users eat less.
People usually see weight reduction within a few weeks of starting on the regular doses.
Studies suggests users may put most of the weight back on after a year of discontinuing the treatment, as their normal hunger come back.
Being overweight or obese raises your chance for contracting health problems, like type 2 diabetes, cardiovascular issues, brain attack, and specific malignancies.
Obesity concerns individuals in countries worldwide and was linked to 3.7 million fatalities worldwide in 2024, as per the health agency.
